Clinical Trials Logo

Glucose Metabolism Disorders clinical trials

View clinical trials related to Glucose Metabolism Disorders.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04824872 Withdrawn - Hypoglycemia Clinical Trials

Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults

Start date: February 2023
Phase: Phase 2
Study type: Interventional

The objective of the trial is to assess the effect of single subcutaneous doses of dasiglucagon versus placebo on post-prandial plasma glucose nadir following a Mixed Meal Test in Roux-en-Y Gastric Bypass (RYGB) subjects

NCT ID: NCT04452786 Withdrawn - Clinical trials for Glucose Metabolism Disorders

Hormonal and Metabolic Aspects of Endoscopic Sleeve Gastroplasty

Start date: June 5, 2020
Phase: N/A
Study type: Interventional

The investigators of the study want to investigate the complex interactions between glucose metabolism, food intake/weight loss, and different appetite regulating hormones after ESG in comparison with conventional laparoscopic sleeve gastrectomy (LSG).

NCT ID: NCT03765008 Withdrawn - Clinical trials for Glucose Metabolism Disorders

The Effect of Water Intake on Glucose Regulation

INDIGO-I
Start date: February 11, 2019
Phase: N/A
Study type: Interventional

There is a growing body of evidence suggesting low water intake and elevated levels of the hormone vasopressin exacerbate glucose regulation. This project will examine the physiological mechanism by which low water intake impairs glucose homeostasis. In the current proposal we aim to: 1) quantify the degree of glucose impairment as a response to elevated vasopressin due to low water intake and 2) identify the physiological mechanism by which elevated vasopressin, as a response to low water intake, impairs glucose regulation

NCT ID: NCT03685773 Withdrawn - Clinical trials for Diabetes Mellitus, Type 2

The Role of Hepatic Denervation in the Dysregulation of Glucose Metabolism in Liver Transplant Recipients

Start date: April 21, 2019
Phase: Phase 2
Study type: Interventional

It is believed that important brain centers send signals through the vagus nerve to the liver to suppress the amount of glucose (sugar) that gets produced. People who have received liver transplants have had their vagus nerve cut during transplantation, and many of these individuals have diabetes at one year post-transplant. The goals of this study are: to see whether metabolic control centers in the brain can still be activated normally with the medication diazoxide in patients who have had a liver transplant, and to understand whether disrupting the vagus nerve would result in excess glucose being produced by the liver (ie. a potential mechanism for why these patients develop diabetes).

NCT ID: NCT03512496 Withdrawn - Health Behavior Clinical Trials

Metabolic and Genetic Impacts of Energy Drinks in Youth

Start date: December 1, 2014
Phase: N/A
Study type: Interventional

Caffeine containing energy drinks (CCED) are beverages that typically contain mixtures of simple sugars, caffeine and may contain vitamin, mineral and/or herbal preparations. In Canada, the consumption of CCEDs among adolescents is a regular occurrence and a common part of the everyday diet. Contributing to the obesity epidemic in youth is the consumption of energy drinks; yet no data on the metabolic responses to CCEDs exists. This study will examine the metabolic implications of CCED consumption in adolescents, aged 13-19 years. The investigators hypothesize that CCEDs will impair glucose tolerance by ~30% in lean adolescents and the primary cause of the insulin resistance will be caffeine. Obese individuals will experience a similar level of glucose impairment, but a greater rise in blood glucose compared to their lean counterparts (i.e. higher starting glucose level). For many, this additional, caffeine-induced rise will expose them to hyperglycemia, putting some individuals in the glucose intolerant or transient diabetic range. It is hypothesized that continued metabolic insult resulting from CCEDs may predispose susceptible individuals to chronic metabolic diseases later in life. The investigators will also examine the genetic basis of caffeine-induced glucose intolerance. This gene-diet interaction could explain why caffeine may be much more metabolically harmful for some individuals compared to others. The study of 'metabolomics' will also be utilized to analyze caffeine and caffeine metabolites such as theobromine, theophylline, and xanthine. This will be accomplished using Nuclear Magnetic Resonance (NMR) spectroscopy. Results from this study will have the potential to alter current perceptions that CCED are 'harmless' and will have far reaching implications for both medical professionals and legislators alike.

NCT ID: NCT00306826 Withdrawn - Clinical trials for Glucose Metabolism Disorders

Pioglitazone in Impaired Glucose Tolerance

Start date: n/a
Phase: Phase 4
Study type: Interventional

In patients with impaired glucose tolerance (IGT), the researchers want to study the relative effects of pioglitazone, simvastatin, or the combination of both on: - intima media thickness (IMT) as an easily assessed marker of atherosclerosis - heart rate variability (HRV) as a marker of autonomic neuropathy - flow-mediated vasodilatation (FMD) of the brachial artery as a marker of endothelial function - vascular and metabolic lab parameters